Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + rituximab vs rituximab in relapsed/refractory indolent NHL
CTR20140716Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), sponsored by Celgene Corporation. Started Nov 2014; status: active.
02
Drugs
lenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20140716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140716.